Press release
CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO ADVANCE CELL THERAPY PROGRAMS
• Financing round was significantly oversubscribed by existing investors and new private investors.• Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.
Melbourne, Australia, 1 October 2024 -  Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M in an oversubscribed financing round.
This funding will support the initiation of the clinical trial for CTH-401, the Company's lead cell therapy product, aimed at treating ovarian cancer, as well as broadening its pipeline to include other disease indications.
Cartherics' Chief Executive Officer, Prof. Alan Trounson AO commented: "The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases."
Despite advancements in surgical and chemotherapy treatments for ovarian cancer, survival rates remain very low. This is largely due to late diagnosis and the lack of options for patients who are refractory to approved therapies, highlighting the need for new treatment options for these patients.
CTH-401 is the only natural killer (NK) cell product currently under development that incorporates a chimeric antigen receptor (CAR) that targets the adenocarcinoma specific antigen, TAG-72. TAG-72 is a well-validated tumour marker that is widely expressed in a range of solid tumours, including ovarian, gastric, colorectal, prostate and pancreatic cancers.
Cartherics has demonstrated that CTH-401 is very effective in killing ovarian cancer cells in both tissue culture and animal models, with initiation of the first clinical trial planned for next year.
Cartherics' Chairman, Bob Moses said: "We are eager to initiate the clinical trial for CTH-401, building on the promising results from our preclinical studies. This important milestone underscores our commitment to delivering innovative treatments for ovarian cancer and highlights the confidence our investors have in our vision to enhance patient outcomes and drive growth."
The global market for ovarian cancer drugs is estimated at US$3.5 billion in 2023 and is projected to reach US$4.8 billion by 2030. The natural killer cell therapeutics market was valued at US$350.5 million in 2024 and is projected to grow at a CAGR of 41.70% to reach US$11.4 billion by 2034.
******
Cartherics Pty Ltd
12 Ferntree Place
Notting Hill
VIC
3168
Media contact
Christine Filippis  
Teraze Communications 
Phone: +61 419 119 866  
Email: christine@teraze.com.au
About Cartherics  
Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia that is rearming the body's immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company's allogeneic ("off-the-shelf") cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific "safe harbour" genomic sites to provide enhanced function for the derived NK and other immune cells. The Company's lead product, CTH-401, is a CAR-NK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.  
https://cartherics.com/ 
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO ADVANCE CELL THERAPY PROGRAMS here
News-ID: 3675411 • Views: …
More Releases from Cartherics

CARTHERICS TO PRESENT AT THE 2025 BIO INTERNATIONAL CONVENTION
• Cartherics' Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US EDT).
Melbourne, Australia, 28 May 2025 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, COO, will present at the upcoming 2025 BIO International Convention June 16-19 2025, in Boston Massachusetts.…

CARTHERICS ENTERS AGREEMENTS WITH UNIQUEST, THE UNIVERSITY OF QUEENSLAND AND THE …
• Cartherics, UniQuest and The University of Sydney enter Technology Licence Agreement for Cartherics' iPSC cell line.
• Cartherics, The University of Queensland and The University of Sydney enter Material Transfer Agreement to support development of iPSC-derived cardiomyocytes for the treatment of cardiovascular disease.
Melbourne, Australia, 25 July 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that…

CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
Melbourne, Australia, 23 May 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.
The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in…

CARTHERICS EXECUTES OPTION AGREEMENT WITH THE OHIO STATE UNIVERSITY: TISSUE FACT …
Melbourne, Australia, 20 March 2024 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio State) covering tissue factor (TF) as a target for chimeric antigen receptor (CAR) natural killer (NK) cells. The Company will utilise its…
More Releases for CAR
Car Washing Services Market Is Booming So Rapidly with Mister Car Wash, Zips Car …
The Car Washing Services Market has been fragmented based on the productivity of several companies; therefore, each segment and its sub-segments are analyzed in the research report. Furthermore, the report offers 360 views on historical and upcoming growth based on volume, value, production, and consumption. Moreover, it classifies depend on sub-segments, key segments as per the significant regions and offers an in-depth analysis on the competitive edge of the market.…
Car Wash Service Market Boosting the Growth Worldwide: Auto Bell Car Wash, Miste …
The latest study released on the Global Car Wash Service Market by AMA Research evaluates market size, trend, and forecast to 2027. The Car Wash Service market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key…
Car Rental Services Market Forecast to 2028 Covid-19 Impact and Global Analysis …
Car rental services are a process of hiring/renting a car for a limited period from a rental company. Various companies like Uber Technologies, Europcar rent the vehicles for a short period ranging from few hours to weeks. The different types of cars rented by the company include Luxury Car, executive car, and economical car among others. Additionally, vehicle renting agencies also offer other products such as insurance, entertainment systems, and…
Car Rentals Market Growth Strategies and Innovative Technology Transformation by …
Worldwide Market Reports has announced the addition of the "Car Rentals Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Car Rentals Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.
The emergence of own-brand digital ordering platform has been trending in the global Car Rentals market. Car Rentals such as…
Luxury Car Leasing Market Competitors Analysis By German Rent A Car, ANI Technol …
'Global Luxury Car Leasing Market Research Report' the report is complete with an elaborate research undertaken by prominent analysts and a detailed analysis of the global industry place. The Luxury Car Leasing report is fragmented in several features which include manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks, entry barriers, sales channels, and distributors which are again elaborated in…
Car Wash Market is Thriving Worldwide 2026 | Super Star Car Wash, Autobell Car W …
This Car Wash Market research report offers you an array of insights about Automotive industry and business solutions that will support to stay ahead of the competition. Systematic investment analysis is also underlined in this Car Wash Market report which forecasts impending opportunities for the market players.This market report is the outcome of persistent efforts lead by knowledgeable forecasters, innovative analysts and brilliant researchers who carries out detailed and diligent…